Note that while they suspended dolcanatide research in the last quarter of 2015 to "conserve cash", their operating loss actually increased, attributed largely to increases in executive compensation. SGYP: 4 years late and a billion dollars short.
No, I didn't miss any of that. But I think you missed the presentation at the recent GI convention which analyzed all the existing trials data and concluded that there was no difference between the two drugs in terms of the incidence of diarrhea.
Given that 145mcg and 290mcg doses of Linzess have been approved and widely prescribed for years, your predictions seem fanciful.
Incidentally, rigorous analysis has demonstrated that in terms of incidence/severity of diarrhea, Liinzess and plecanatide are roughly equal.